Abstract

On the basis of the change in depression scores on the QIDS-SR-16 at week 6, this trial did not show a significant difference in antidepressant effects between psilocybin and escitalopram in a selected group of patients. Secondary outcomes generally favored psilocybin over escitalopram, but the analyses of these outcomes lacked correction for multiple comparisons. Larger and longer trials are required to compare psilocybin with established antidepressants. (Funded by the Alexander Mosley Charitable Trust and Imperial College London's Centre for Psychedelic Research; ClinicalTrials.gov number, NCT03429075.).

Keywords

PsilocybinEscitalopramDepression (economics)PsychologyPsychiatryHallucinogenMedicineAnxietyAntidepressant

Affiliated Institutions

Related Publications

Endogenomorphic Depression

Donald F. Klein

This report reviews conflicts in delineating the phenomena of depression with an emphasis on the central criterion role of the symptomatic pattern of the nonprecipitated (endoge...

1974 Archives of General Psychiatry 592 citations

Publication Info

Year
2021
Type
article
Volume
384
Issue
15
Pages
1402-1411
Citations
1223
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1223
OpenAlex

Cite This

Robin Carhart‐Harris, Bruna Giribaldi, Rosalind Watts et al. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine , 384 (15) , 1402-1411. https://doi.org/10.1056/nejmoa2032994

Identifiers

DOI
10.1056/nejmoa2032994